Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Treatment Strategy for Rifampin-Susceptible Tuberculosis
Nicholas I. Paton, C S G Cousins, Celina Suresh, et al.
New England Journal of Medicine (2023) Vol. 388, Iss. 10, pp. 873-887
Open Access | Times Cited: 90

Showing 1-25 of 90 citing articles:

Therapeutic developments for tuberculosis and nontuberculous mycobacterial lung disease
Véronique Dartois, Thomas Dick
Nature Reviews Drug Discovery (2024) Vol. 23, Iss. 5, pp. 381-403
Open Access | Times Cited: 35
Acute liver failure
Rakhi Maiwall, Anand V. Kulkarni, Juan Pablo Arab, et al.
The Lancet (2024) Vol. 404, Iss. 10454, pp. 789-802
Closed Access | Times Cited: 23
Oral Regimens for Rifampin-Resistant, Fluoroquinolone-Susceptible Tuberculosis
Lorenzo Guglielmetti, Uzma Khan, Gustavo E. Velásquez, et al.
New England Journal of Medicine (2025) Vol. 392, Iss. 5, pp. 468-482
Closed Access | Times Cited: 4
Tuberculosis
Anete Trajman, Jonathon R. Campbell, Tenzin Kunor, et al.
The Lancet (2025) Vol. 405, Iss. 10481, pp. 850-866
Closed Access | Times Cited: 4
Scientific advances and the end of tuberculosis: a report from the Lancet Commission on Tuberculosis
Michael Reid, Yvan Jean Patrick Agbassi, Nimalan Arinaminpathy, et al.
The Lancet (2023) Vol. 402, Iss. 10411, pp. 1473-1498
Closed Access | Times Cited: 37
Recent advances in the treatment of tuberculosis
Ilaria Motta, Martin J. Boeree, Dumitru Chesov, et al.
Clinical Microbiology and Infection (2023) Vol. 30, Iss. 9, pp. 1107-1114
Open Access | Times Cited: 35
A half-century of research on tuberculosis: Successes and challenges
Barry R. Bloom
The Journal of Experimental Medicine (2023) Vol. 220, Iss. 9
Open Access | Times Cited: 26
Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial
Müge Çevik, Lindsay C Thompson, Caryn M. Upton, et al.
The Lancet Infectious Diseases (2024) Vol. 24, Iss. 9, pp. 1003-1014
Open Access | Times Cited: 16
Target regimen profiles for tuberculosis treatment
Christian Lienhardt, Kelly E. Dooley, Payam Nahid, et al.
Bulletin of the World Health Organization (2024) Vol. 102, Iss. 08, pp. 600-607
Open Access | Times Cited: 10
Patient Determinants and Effects on Adherence of Adverse Drug Reactions to Tuberculosis Treatment: A Prospective Cohort Analysis
Christine Tzelios, Samantha Malatesta, Tara Carney, et al.
Clinical Infectious Diseases (2025)
Closed Access | Times Cited: 1
Bronchoscopic valve therapy for tuberculosis: a scoping review
Kshitij Agarwal, Adam Thorburn Gray, Tudor Toma, et al.
Monaldi Archives for Chest Disease (2025)
Open Access | Times Cited: 1
A Nanopore Sequencing-based Pharmacogenomic Panel to Personalize Tuberculosis Drug Dosing
Renu Verma, Késia Esther da Silva, Neesha Rockwood, et al.
American Journal of Respiratory and Critical Care Medicine (2024) Vol. 209, Iss. 12, pp. 1486-1496
Open Access | Times Cited: 8
Opportunities and limitations of genomics for diagnosing bedaquiline-resistant tuberculosis: a systematic review and individual isolate meta-analysis
Camus Nimmo, Neda Bionghi, Matthew J. Cummings, et al.
The Lancet Microbe (2024) Vol. 5, Iss. 2, pp. e164-e172
Open Access | Times Cited: 7
Tuberculosis treatment-shortening
Vinayak Singh
Drug Discovery Today (2024) Vol. 29, Iss. 5, pp. 103955-103955
Open Access | Times Cited: 7
Economic implications of novel regimens for tuberculosis treatment in three high-burden countries: a modelling analysis
Theresa Ryckman, Samuel G. Schumacher, Christian Lienhardt, et al.
The Lancet Global Health (2024) Vol. 12, Iss. 6, pp. e995-e1004
Open Access | Times Cited: 7
Candidate anti-tuberculosis medicines and regimens under clinical evaluation
Michael Höelscher, David Barros-Aguirre, Masoud Dara, et al.
Clinical Microbiology and Infection (2024) Vol. 30, Iss. 9, pp. 1131-1138
Open Access | Times Cited: 7
High-dose, short-duration versus standard rifampicin for tuberculosis preventive treatment: a partially blinded, three-arm, non-inferiority, randomised, controlled trial
Rovina Ruslami, Federica Fregonese, Lika Apriani, et al.
The Lancet Respiratory Medicine (2024) Vol. 12, Iss. 6, pp. 433-443
Closed Access | Times Cited: 5
Baseline and treatment-emergent bedaquiline resistance in drug-resistant tuberculosis: a systematic review and meta-analysis
Rubeshan Perumal, Neda Bionghi, Camus Nimmo, et al.
European Respiratory Journal (2023) Vol. 62, Iss. 6, pp. 2300639-2300639
Open Access | Times Cited: 13
Target product profiles: tests for tuberculosis treatment monitoring and optimization
Ankur Gupta‐Wright, Saskia den Boon, Emily MacLean, et al.
Bulletin of the World Health Organization (2023) Vol. 101, Iss. 11, pp. 730-737
Open Access | Times Cited: 11
Subclinical tuberculosis: a meta-analysis of prevalence and scoping review of definitions, prevalence and clinical characteristics
Alvin Kuo Jing Teo, Emily MacLean, Greg J. Fox
European Respiratory Review (2024) Vol. 33, Iss. 172, pp. 230208-230208
Open Access | Times Cited: 4
Shorter TB treatment regimens should be safer as well
Oxana Rucsineanu, P. Agbassi, Rosa María Blanca Herrera, et al.
Public Health Action (2023) Vol. 13, Iss. 3, pp. 104-106
Open Access | Times Cited: 10
The microbiome and the gut-lung axis in tuberculosis: interplay in the course of disease and treatment
Néstor Alvarado-Peña, David Galeana-Cadena, Itzel Alejandra Gómez-García, et al.
Frontiers in Microbiology (2023) Vol. 14
Open Access | Times Cited: 10
Safety of Triple-Dose Rifampin in Tuberculosis Treatment: A Systematic Review and Meta-Analysis
Omri Avraham Arbiv, Thomas W. Holmes, Marie JeongMin Kim, et al.
Clinical Infectious Diseases (2025)
Closed Access
Tuberculosis: An Update for the Clinician
Saskia Janssen, Melissa Murphy, Caryn M. Upton, et al.
Respirology (2025)
Open Access
Update in tuberculosis treatment: a scoping review of current practices
Samuel Campos Lopes, Mariana Marçal, N Fernandes, et al.
Breathe (2025) Vol. 21, Iss. 1, pp. 240232-240232
Open Access
Page 1 - Next Page

Scroll to top